High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
We hypothesize that higher dose icotinib is related with better efficacy. The primary
objective is to compare the progression-free survival of higher dose and routine dose of
icotinib in treating pretreated advanced non-small cell lung cancer patients with stable
disease after 8-week routine dose icotinib treatment.